NOXOPHARM-LIMITED
18.3.2021 13:02:04 CET | Business Wire | Press release
Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announced that Veyonda has been approved to move into the second and final stage of the NOXCOVID-1 clinical trial on the advice of the study’s clinicians.
Part 1 of the NOXCOVID-1 trial involved 26 patients and was a dose-escalation arm testing the safety of increasing (400, 600, 800, 1200, 1800 mg) daily Veyonda dosages. The 1800 mg dose was deemed to be sufficiently well tolerated in patients with moderate COVID-19 disease to become the preferred dose. The high tolerance of the drug by patients with very poor lung function provides further evidence of the safety of Veyonda in patients with acute illness.
Noxopharm CEO Dr. Graham Kelly said, “The high potency of Veyonda in blocking cytokine release from damaged tissue in the laboratory meant we were obliged to adopt a very cautious and methodical approach when being used for the first time in patients with poor lung function. We can now be confident that Veyonda, despite its potency, is well tolerated at a dosage we believe will be therapeutic.”
Part 2 of the NOXCOVID-1 trial now is starting to recruit a minimum of 10 and up to 15 patients with moderate-to-severe lung dysfunction. Patients will be treated for up to 14 days with an 1800 mg Veyonda dose each day.
Noxopharm is committed to pursuing its NOXCOVID program for two main reasons: Despite the advent of COVID-19 vaccines, emerging news of new mutant strains of the virus points to a likely ongoing long-term need for effective treatments for COVID-19 patients who go on to develop long-term lung damage and are at high risk of septic shock.
The current pandemic represents a small proportion of patients who die each year from septic shock. Even once the pandemic abates, the need for an effective and safe ongoing treatment for septic shock will remain.
About Noxopharm
Noxopharm is a clinical-stage Australian oncology drug development company with offices in Sydney and New York. The company has a primary focus on the development of Veyonda and is the major shareholder in the nononcology drug development company, Nyrada Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210318005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Diligent Unveils AI Board Member and Agentic GRC Workforce at Elevate 202623.4.2026 15:00:00 CEST | Press release
Diligent’s agentic AI strengthens board oversight and transforms how GRC teams work — reducing manual effort and outside-advisor dependency, tightening control over sensitive workflows and enabling leaders to make faster, more defensible decisions Diligent, the AI leader in governance, risk and compliance (GRC) SaaS solutions, today unveiled a new generation of autonomous AI agents, including AI Board Member — a secure AI assistant for directors — and a coordinated network of agents embedded across the Diligent One Platform. Accessible through a single command center, agents automate multi-step workflows across governance, risk, compliance and third-party management, giving organizations the impact of a “GRC manager” without adding headcount. “AI supercharges teams that embrace it, and boards are no exception,” said Brian Stafford, President and CEO of Diligent. “With AI Board Member and a network of autonomous agents woven through the Diligent One Platform, we’re giving the C-suite an
Safe Software Bolsters Leadership Team with CFO and CPO Appointments to Drive Next Phase of Growth23.4.2026 15:00:00 CEST | Press release
CFO and CPO executive hires to enhance operational and financial performance on the company’s path to $250M by 2028 Safe Software (Safe), creator of FME, the only All-Data, Any-AI enterprise integration platform, today welcomes two executives to its leadership team as it moves into the next phase of growth. Judd Lee has been appointed as the company’s Chief Financial Officer (CFO), and Vanessa Ribreau has been appointed as Chief People Officer (CPO). Having recently crossed $100M in revenue, the expanded leadership team will further enable the company to scale as it accelerates toward its goal of reaching $250M in revenue by 2028. Judd Lee is a seasoned CFO with over 15 years of experience partnering closely with CEOs to align financial strategy and accelerate sustainable growth. He is known for his strong commitment to mentorship and for building high-performing global teams rooted in trust, morale and a shared sense of purpose. With more than two decades of financial leadership acros
Corpay Cross-Border Named the Official FX Supplier of Toulouse Football Club23.4.2026 14:30:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Toulouse Football Club to become their Official Foreign Exchange (FX) Supplier. A partnership brought together by SPORTFIVE, an international sports marketing agency. Through this partnership, Corpay Cross-Border will deliver comprehensive FX risk management solutions to support Toulouse Football Club’s operations. In addition, its award-winning platform will enable the club to manage global payments seamlessly through a single point of access. “Corpay Cross-Border is proud to be named the Official FX Supplier of Toulouse Football Club,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “This partnership reinforces Corpay’s position as a leading provider of corporate payments and currency risk management solutions within prof
Philip Morris International Expands its Partnership with Ducati Corse as Decades-Long Partnership Races Forward with Purpose23.4.2026 14:00:00 CEST | Press release
ZYN branding to be present at select MotoGP races in the 2026 season and beyond Philip Morris International1 (NYSE: PM) today announced an expanded partnership with Ducati Corse for the 2026 season and beyond. This next chapter introduces a major development: the ZYN brand of nicotine pouches—the number one nicotine pouch brand globally2—will feature on Ducati Corse MotoGP liveries at select races throughout the seasons. Just as Ducati pushes the limits of performance, ZYN represents PMI’s commitment to delivering innovation, offering a product that delivers exceptional quality while being thoughtfully designed. This partnership allows ZYN to connect with adult consumers in a space they’re passionate about—and to do so in a way that’s authentic, respectful, and dynamic. Philip Morris International’s relationship with Ducati Corse began in 2003—the year Ducati arrived in MotoGP—ushering in a bold new era of ambition. Since then, the collaboration has evolved alongside both organizations
Vitrealab and poLight ASA Partner to Tackle Coherence Artifacts in Laser-LCoS AR Displays23.4.2026 14:00:00 CEST | Press release
Vitrealab GmbH and poLight ASA (OSE: PLT) today announced a collaboration to advance laser illumination architectures for LCoS-based augmented reality (AR) displays, with a focus on mitigating coherence-related image artifacts while preserving system efficiency and compactness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423345474/en/ Vitrealab GmbH and poLight ASA (OSE: PLT) today announced a collaboration to advance laser illumination architectures for LCoS-based augmented reality (AR) displays, with a focus on mitigating coherence-related image artifacts while preserving system efficiency and compactness. Vitrealab’s Quantum Light Chip combined with poLight's TWedge® wobulation technology helps create a higher performing and more manufacturable AR system. Laser-based illumination offers clear system-level advantages for LCoS based AR light engines, including high optical efficiency due to intrinsic polarization, imp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom